Semaglutide
Wegovy (Chronic weight management) · Ozempic (Type 2 diabetes) · Rybelsus (Type 2 diabetes (oral))
The molecule that created this market. Weekly injectable GLP-1 agonist, the most widely prescribed agent across employer programs and the one your pharmacy trend is most likely driven by.
- Vendors covering
- 12
- Administration
- Once-weekly subcutaneous injection
- List cost
- $1,000–$1,350 per month at list, before rebates
Vendor coverage
Who prescribes Semaglutide, and on what terms
The access column is the one that moves your budget. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
| Vendor | Access | Gating | Score | PMPM |
|---|---|---|---|---|
| Virta Health Reviews Semaglutide Metabolic specialist | Escalation only | Type 2 diabetes or prediabetes required, plus a documented failure to reach targets on the nutritional protocol. | 8.7 | $40–$95 |
| Omada Health Reviews Semaglutide Coaching companion | Companion support | None from Omada. Access is governed entirely by whatever rules your PBM already enforces. | 8.4 | $32–$58 |
| Form Health Reviews Semaglutide Full-service clinical | First-line | BMI ≥ 30, or ≥ 27 with comorbidity. Prior authorization and step therapy both apply. | 8.0 | $58–$105 |
| Twin Health Reviews Semaglutide Metabolic specialist | Escalation only | Type 2 diabetes or prediabetes required, plus sensor-documented failure to reach targets on the nutritional protocol. | 7.8 | $55–$120 |
| Found Reviews Semaglutide Full-service clinical | Escalation only | BMI ≥ 27, prior authorization, and a documented inadequate response to a lower-cost agent first. | 7.6 | $45–$85 |
| Vida Health Reviews Semaglutide Full-service clinical | Escalation only | BMI ≥ 27, prior authorization, step therapy, and completed behavioral-health screening before initiation. | 7.5 | $38–$78 |
| Teladoc Health Reviews Semaglutide Navigation & orchestration | First-line | Whatever you configure. Defaults are conservative, but the ceiling and floor are yours to set. | 7.4 | $18–$44 |
| 9amHealth Reviews Semaglutide Metabolic specialist | Escalation only | BMI ≥ 27 or a cardiometabolic diagnosis, prior authorization, and documented failure on generic therapy first. | 7.3 | $34–$72 |
| Calibrate Reviews Semaglutide Full-service clinical | First-line | BMI ≥ 30, or ≥ 27 with a comorbidity. Prior authorization required, but no step therapy stands between an eligible member and this molecule. | 7.2 | $65–$110 |
| Transcarent Reviews Semaglutide Navigation & orchestration | Orchestrated | Fully employer-configurable and applied uniformly across all downstream vendors. | 7.1 | $12–$32 |
| WeightWatchers Clinic Reviews Semaglutide Consumer-brand clinical | First-line | BMI ≥ 27 with comorbidity, or ≥ 30. Prior authorization required. | 6.9 | $30–$68 |
| Noom Med Reviews Semaglutide Consumer-brand clinical | First-line | BMI ≥ 27. No step therapy and no prior authorization requirement from Noom itself. | 6.6 | $28–$62 |
Clinical profile
How Semaglutide works
- Mechanism
- Mimics endogenous GLP-1: slows gastric emptying, increases satiety signaling, and stimulates glucose-dependent insulin secretion. The appetite effect, not the glycemic effect, drives the weight outcome.
- Administration
- Once-weekly subcutaneous injection. An oral daily formulation exists but is indicated for type 2 diabetes rather than weight management.
- Titration
- Typically initiated at a low weekly dose and escalated in steps roughly every four weeks over four to five months to the maintenance dose. That escalation window is where most discontinuation happens.
- Typical result
- In registrational trials, average body-weight reduction in the mid-teens as a percentage at roughly 68 weeks. Real-world results run materially lower, driven almost entirely by discontinuation rather than by non-response.
- List cost
- Roughly $1,000–$1,350 per month at list, before rebates
Known side effects
- Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — concentrated during dose escalation
- Gallbladder events and pancreatitis reported at low rates
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
- Meaningful lean-mass loss alongside fat mass during rapid reduction
For benefits teams
What Semaglutide means for your budget
Indication arbitrage is a real budget risk
The same molecule is marketed under different brands for diabetes and for weight management, at different price points and under different coverage rules. Programs that do not tightly specify which indication and which brand they cover routinely find spend landing somewhere they did not model.
Titration is where your money is won or lost
Members who discontinue during escalation generate close to a full course of cost and close to zero durable benefit. The single most valuable thing a clinical vendor can do for your budget on this molecule is keep people through the escalation window.
Supply has been volatile
Availability of this molecule has shifted more than once, and vendors whose pricing depended on non-standard supply have had to re-price. Ask any vendor how their semaglutide economics changed through those periods and why.